Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
DISHMAN PHARMA | CIPLA | DISHMAN PHARMA/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 35.6 | 70.5% | View Chart |
P/BV | x | 3.3 | 4.1 | 81.0% | View Chart |
Dividend Yield | % | 0.7 | 0.5 | 134.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
CIPLA Mar-20 |
DISHMAN PHARMA/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 586 | 63.9% | |
Low | Rs | 129 | 357 | 36.1% | |
Sales per share (Unadj.) | Rs | 197.8 | 207.0 | 95.5% | |
Earnings per share (Unadj.) | Rs | 21.2 | 18.6 | 114.0% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 33.2 | 104.7% | |
Dividends per share (Unadj.) | Rs | 2.00 | 4.00 | 50.0% | |
Dividend yield (eoy) | % | 0.8 | 0.8 | 93.6% | |
Book value per share (Unadj.) | Rs | 179.9 | 195.5 | 92.0% | |
Shares outstanding (eoy) | m | 80.69 | 806.35 | 10.0% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 1.3 | 2.3 | 55.9% | |
Avg P/E ratio | x | 11.9 | 25.3 | 46.8% | |
P/CF ratio (eoy) | x | 7.2 | 14.2 | 51.0% | |
Price / Book Value ratio | x | 1.4 | 2.4 | 58.0% | |
Dividend payout | % | 9.4 | 21.5 | 43.8% | |
Avg Mkt Cap | Rs m | 20,306 | 379,912 | 5.3% | |
No. of employees | `000 | 0.8 | 25.8 | 3.2% | |
Total wages/salary | Rs m | 5,355 | 30,270 | 17.7% | |
Avg. sales/employee | Rs Th | 19,252.7 | 6,459.6 | 298.0% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,171.2 | 551.5% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 580.2 | 355.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 166,949 | 9.6% | |
Other income | Rs m | 265 | 3,442 | 7.7% | |
Total revenues | Rs m | 16,226 | 170,391 | 9.5% | |
Gross profit | Rs m | 4,103 | 32,060 | 12.8% | |
Depreciation | Rs m | 1,091 | 11,747 | 9.3% | |
Interest | Rs m | 944 | 1,974 | 47.9% | |
Profit before tax | Rs m | 2,334 | 21,782 | 10.7% | |
Minority Interest | Rs m | 0 | -475 | 0.0% | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 6,312 | 9.9% | |
Profit after tax | Rs m | 1,711 | 14,995 | 11.4% | |
Gross profit margin | % | 25.7 | 19.2 | 133.9% | |
Effective tax rate | % | 26.7 | 29.0 | 92.2% | |
Net profit margin | % | 10.7 | 9.0 | 119.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 117,038 | 9.4% | |
Current liabilities | Rs m | 9,517 | 43,931 | 21.7% | |
Net working cap to sales | % | 9.4 | 43.8 | 21.5% | |
Current ratio | x | 1.2 | 2.7 | 43.5% | |
Inventory Days | Days | 110 | 96 | 115.4% | |
Debtors Days | Days | 35 | 85 | 40.9% | |
Net fixed assets | Rs m | 16,304 | 107,424 | 15.2% | |
Share capital | Rs m | 161 | 1,613 | 10.0% | |
"Free" reserves | Rs m | 12,907 | 156,018 | 8.3% | |
Net worth | Rs m | 14,516 | 157,630 | 9.2% | |
Long term debt | Rs m | 4,189 | 23,693 | 17.7% | |
Total assets | Rs m | 29,805 | 236,626 | 12.6% | |
Interest coverage | x | 3.5 | 12.0 | 28.8% | |
Debt to equity ratio | x | 0.3 | 0.2 | 192.0% | |
Sales to assets ratio | x | 0.5 | 0.7 | 75.9% | |
Return on assets | % | 8.9 | 7.2 | 124.2% | |
Return on equity | % | 11.8 | 9.5 | 123.9% | |
Return on capital | % | 17.5 | 12.8 | 136.5% | |
Exports to sales | % | 24.8 | 33.0 | 75.0% | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | 55,175 | 7.2% | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 56,036 | 8.8% | |
Fx outflow | Rs m | 697 | 6,764 | 10.3% | |
Net fx | Rs m | 4,255 | 49,272 | 8.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 30,685 | 9.1% | |
From Investments | Rs m | -1,529 | 1,040 | -147.0% | |
From Financial Activity | Rs m | -941 | -29,488 | 3.2% | |
Net Cashflow | Rs m | 316 | 2,340 | 13.5% |
Indian Promoters | % | 61.4 | 16.0 | 383.8% | |
Foreign collaborators | % | 0.0 | 20.8 | - | |
Indian inst/Mut Fund | % | 3.7 | 12.2 | 30.3% | |
FIIs | % | 12.7 | 23.7 | 53.6% | |
ADR/GDR | % | 0.0 | 1.1 | - | |
Free float | % | 22.1 | 26.2 | 84.4% | |
Shareholders | 46,261 | 161,166 | 28.7% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: STERLING BIOTECH SANOFI INDIA ALEMBIC PHARMA SHASUN PHARMA NOVARTIS
Compare DISHMAN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More